Ra Medical re-ups $86m IPO registration
Ra Medical has re-upped its registration for an upcoming initial public offering looking to bring in approximately $86.3 million, according to a recently posted SEC filing. Ra Medical produces the Dabra atherectomy catheter laser designed to treat patients with peripheral artery disease. The system is designed to destroy arteriosclerotic blockages through the use of radiation ablation, which the company touts as having significant advantages over traditional balloon angioplasty systems. Ra Medical won FDA 510(k) clearance for the system last May, and CE Mark approval in the European Union in 2016. The Carlsbad, Calif.-based company originally registered for the IPO in July, saying it plans to list on the New York Stock Exchange under the symbol “RMED,” according to the filing. Piper Jaffray and Cantor Fitzgerald are acting as joint book runners for the offering, according to the newly posted filing. The company has not yet released details on the IPO, but had initially planned to launch the offering in February this year. The post Ra Medical re-ups $86m IPO registration appeared first on MassDevice.
The most common clinical presentation of peripheral artery disease (PAD) comprises intermittent claudication though about one third of patients will progress to below-the-knee critical limb ischemia. Currently, percutaneous transluminal angioplasty (PTA) is the standard endovascular therapy employed in this patient population. The Lutonix BTK IDE multicenter randomized study was conducted to assess the safety and efficacy of the Lutonix DCB for the treatment of stenosis or occlusion of native below-the-knee arteries.
Intimal hyperplasia (IH) is the most common indicator for secondary intervention in peripheral vascular disease. Matrix metalloproteinases (MMPs) play a role in IH development due to their degradation of the extracellular matrix. Doxycycline, a member of the tetracycline family of antibiotics, is a potent MMP inhibitor. We have previously shown doxycycline inhibits MMP activity and VSMC migration in vitro. We hypothesized that doxycycline would decrease MMP activity in vivo and inhibit the development of IH in a rodent model of vascular injury.
Intimal hyperplasia (IH) is the most common indicator for secondary intervention in peripheral vascular disease. Matrix metalloproteinases (MMPs) play a role in IH development due to their degradation of the extracellular matrix. Doxycycline (Doxy), a member of the tetracycline family of antibiotics, is a potent MMP inhibitor. We have previously shown that Doxy inhibits MMP activity and vascular smooth muscle cell migration in vitro. We hypothesized that Doxy would decrease MMP activity in vivo and inhibit the development of IH in a rodent model of vascular injury.
A meta-analysis of randomized clinical trials concluded that there is an increased risk of death for patients treated with paclitaxelâcoated balloons and stents in the femoral and/or popliteal arteriesÂ of the lower limbs. At least two drug-eluting device trials have been paused since this analysis was published late last month in the Journal of the American Heart AssociationÂ (JAHA). Investigators of the BASIL-3 trial and the SWEDEPAD 1 and SWEDEPAD 2 trials have paused recruitment efforts in response to the published findings.Â Konstantinos Katsanos, MD, PhDÂ ...
CONCLUSIONS: The risk factors obtained from the medical history and during the hospitalisation improve the risk stratification during the post-discharge period after hospitalisation for ACS. PMID: 29350382 [PubMed - indexed for MEDLINE]
At last week's Vascular Interventional Advances (VIVA) Annual Meeting in Las Vegas, Medtronic presented five-year final outcomes from its IN.PACT SFA Trial. Of note: Medtronic is the first company to present long-term five-year outcomes for a commercially-available drug-coated balloon (DCB). The data not only reinforced the safety, durability, and efficacy of the IN.PACT Admiral DCB, as seen in previous studies, but also reaffirmed its use as a frontline therapy for the treatment of peripheral artery disease (PAD).
Publication date: Available online 14 October 2018Source: Journal of Cardiology CasesAuthor(s): Kuniyasu Ikeoka, Keita Okayama, Tetsuya Watanabe, Shinsuke Nanto, Yasushi Sakata, Shiro HoshidaAbstractA 47-year-old female patient was admitted with a complaint of severe chest pain on effort. She had a history of effort angina treated using coronary artery bypass with left internal thoracic arterial bypass to the left ascending coronary artery. She also had left subclavian and vertebral arterial stenoses, which were treated with balloon-expandable stents. Exercise stress myocardial perfusion imaging revealed anterior to apex l...
CONCLUSIONS: Patients treated with DES had higher lesion and vessel patency than BMS after adjusting for confounding, which included complexity of lesion characteristics and operators' clinical decision-making regarding selection of treatment modalities, in femoropopliteal endovascular interventions in a real-world registry. PMID: 30279293 [PubMed - in process]
Ra Medical yesterday set the terms for its forthcoming initial public offering, which would fetch $50 million at the midpoint. The Carlsbad, Calif.-based company said it plans to float 3.3 million shares at $14 to $16 apiece, for gross proceeds of $46.7 million to $53.3 million. At the midpoint the flotation would gross $50.0 million, according to a new filing with the U.S. Securities &Exchange Commission. That’s well below the more than $86 million Ra Medical indicated in a regulatory filing last month. The company makes the Dabra atherectomy catheter laser to treat patients with peripheral artery disease. ...
This study sought to assess clinical outcomes of a single-center experience following drug-coated balloon (DCB) angioplasty in patients with TransAtlantic Inter-Society Consensus (TASC) II types C and D femoropopliteal peripheral artery disease (PAD).